Management of secondary progressive multiple sclerosis: Prophylactic treatment - Past, present, and future aspects

Paulus S. Rommer, Olaf Stüve

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Opinion statement: Whereas the number of treatment options in relapsing-remitting multiple sclerosis (RRMS) is growing constantly, alternatives are rare in the case of secondary-progressive multiple sclerosis (SPMS). Besides mitoxantrone in North America and Europe, interferon beta-1b and beta-1a are approved for treatment in Europe. Glucocorticosteroids, azathioprine, intravenous immunoglobulins (IVIG) and cyclophosphamide (CYC), although not approved, are commonly utilized in SPMS. Currently monoclonal antibodies (mab), and masitinib are under examination for treatment for SPMS. Hematopoietic stem cell transplantation and immunoablative stem cell transplantation are therapies with the aim of reconstitution of the immune system. This review gives information on the different therapeutics and the trials that tested them. Pathophysiological considerations are presented in view of efficacy of the therapeutics. In addition, therapeutics that showed no efficacy in trials or with unacceptable side effects are topics of this review.

Original languageEnglish (US)
Pages (from-to)241-258
Number of pages18
JournalCurrent Treatment Options in Neurology
Volume15
Issue number3
DOIs
StatePublished - Jun 1 2013

Keywords

  • Azathioprine
  • Cyclophosphamide
  • Daclizumab
  • Glucocorticosteroids
  • Interferon beta-1a
  • Interferon beta-1b
  • Intravenous immunoglobulins
  • Linomide
  • Management
  • Masitinib
  • Mitoxantrone
  • Prophylactic treatment
  • Rituximab
  • Secondary progressive multiple sclerosis
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Management of secondary progressive multiple sclerosis: Prophylactic treatment - Past, present, and future aspects'. Together they form a unique fingerprint.

  • Cite this